Iosulamide is triiodobenzoic acid derivative patented by Sterling Drug Inc as an X-ray contrast agent. Iosulamide shows clear advantages in animal tests over meglumine iodipamide. The intravenous toxicity of Iosulamide meglumine is considerably lower than that of iodipamide (Cholografin) in the mouse and rat. Studies of biliary and urinary excretion patterns indicate Iosulamide is rapidly excreted compared to iodipamide, while at the same time providing equal concentrations in bile. More efficient blood to bile clearance rate and a shorter blood half-life for Iosulamide may account for the lower circulating blood levels and rapid total excretion compared to iodipamide. Iosulamide's rapid blood-bile clearance coupled with its extremely low toxicity may allow rapid administration of high doses, affording superior visualization and safety compared to iodipamide.